TY - JOUR AU - Wei, S. C. AU - Duffy, C. R. AU - Allison, J. P. PY - 2018 DA - 2018// TI - Fundamental mechanisms of immune checkpoint blockade therapy JO - Cancer Discov VL - 8 UR - https://doi.org/10.1158/2159-8290.CD-18-0367 DO - 10.1158/2159-8290.CD-18-0367 ID - Wei2018 ER - TY - JOUR AU - Mellman, I. AU - Coukos, G. AU - Dranoff, G. PY - 2011 DA - 2011// TI - Cancer immunotherapy comes of age JO - Nature. VL - 480 UR - https://doi.org/10.1038/nature10673 DO - 10.1038/nature10673 ID - Mellman2011 ER - TY - JOUR AU - Schreiber, R. D. AU - Old, L. J. AU - Smyth, M. J. PY - 2011 DA - 2011// TI - Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion JO - Science. VL - 331 UR - https://doi.org/10.1126/science.1203486 DO - 10.1126/science.1203486 ID - Schreiber2011 ER - TY - JOUR AU - Velasco, G. AU - Je, Y. AU - Bosse, D. PY - 2017 DA - 2017// TI - Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in Cancer patients JO - Cancer Immunol Res VL - 5 UR - https://doi.org/10.1158/2326-6066.CIR-16-0237 DO - 10.1158/2326-6066.CIR-16-0237 ID - Velasco2017 ER - TY - JOUR AU - Heinzerling, L. AU - Ascierto, P. A. AU - Dummer, R. PY - 2019 DA - 2019// TI - Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology JO - Eur J Cancer VL - 112 UR - https://doi.org/10.1016/j.ejca.2019.01.015 DO - 10.1016/j.ejca.2019.01.015 ID - Heinzerling2019 ER - TY - JOUR AU - Haanen, J. AU - Carbonnel, F. AU - Robert, C. PY - 2018 DA - 2018// TI - Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up JO - Ann Oncol VL - 29 UR - https://doi.org/10.1093/annonc/mdy162 DO - 10.1093/annonc/mdy162 ID - Haanen2018 ER - TY - JOUR AU - Kyi, C. AU - Hellmann, M. D. AU - Wolchok, J. D. PY - 2014 DA - 2014// TI - Opportunistic infections in patients treated with immunotherapy for cancer JO - J Immunother Cancer VL - 2 UR - https://doi.org/10.1186/2051-1426-2-19 DO - 10.1186/2051-1426-2-19 ID - Kyi2014 ER - TY - JOUR AU - Fishman, J. a. y. A. AU - Hogan, J. o. h. n. I. AU - Maus, M. a. r. c. e. l. a. V. PY - 2018 DA - 2018// TI - Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies JO - Clinical Infectious Diseases VL - 69 UR - https://doi.org/10.1093/cid/ciy1025 DO - 10.1093/cid/ciy1025 ID - Fishman2018 ER - TY - JOUR AU - Castillo, M. AU - Romero, F. A. AU - Arguello, E. PY - 2016 DA - 2016// TI - The Spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma JO - Clin Infect Dis VL - 63 UR - https://doi.org/10.1093/cid/ciw539 DO - 10.1093/cid/ciw539 ID - Castillo2016 ER - TY - JOUR AU - Dobler, C. l. a. u. d. i. a. C. AU - Cheung, K. e. l. v. i. n. AU - Nguyen, J. o. h. n. AU - Martin, A. n. d. r. e. w. PY - 2017 DA - 2017// TI - Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis JO - European Respiratory Journal VL - 50 UR - https://doi.org/10.1183/13993003.00157-2017 DO - 10.1183/13993003.00157-2017 ID - Dobler2017 ER - TY - JOUR AU - Cheng, M. P. AU - Abou Chakra, C. N. AU - Yansouni, C. P. PY - 2017 DA - 2017// TI - Risk of active tuberculosis in patients with Cancer: a systematic review and meta-analysis JO - Clin Infect Dis VL - 64 UR - https://doi.org/10.1093/cid/cix209 DO - 10.1093/cid/cix209 ID - Cheng2017 ER - TY - JOUR AU - Hasan, T. AU - Au, E. AU - Chen, S. PY - 2018 DA - 2018// TI - Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines JO - BMJ Open VL - 8 UR - https://doi.org/10.1136/bmjopen-2018-022445 DO - 10.1136/bmjopen-2018-022445 ID - Hasan2018 ER - TY - JOUR AU - Dobler, C. C. AU - McDonald, S. P. AU - Marks, G. B. PY - 2011 DA - 2011// TI - Risk of tuberculosis in dialysis patients: a nationwide cohort study JO - PLoS One VL - 6 UR - https://doi.org/10.1371/journal.pone.0029563 DO - 10.1371/journal.pone.0029563 ID - Dobler2011 ER - TY - JOUR AU - Aguado, J. M. AU - Torre-Cisneros, J. AU - Fortun, J. PY - 2009 DA - 2009// TI - Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology JO - Clin Infect Dis VL - 48 UR - https://doi.org/10.1086/597590 DO - 10.1086/597590 ID - Aguado2009 ER - TY - JOUR AU - Budak-Alpdogan, T. AU - Tangun, Y. AU - Kalayoglu-Besisik, S. PY - 2000 DA - 2000// TI - The frequency of tuberculosis in adult allogeneic stem cell transplant recipients in Turkey JO - Biol Blood Marrow Transplant VL - 6 UR - https://doi.org/10.1016/S1083-8791(00)70013-9 DO - 10.1016/S1083-8791(00)70013-9 ID - Budak-Alpdogan2000 ER - TY - JOUR AU - Askling, J. AU - Fored, C. M. AU - Brandt, L. PY - 2005 DA - 2005// TI - Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden JO - Arthritis Rheum VL - 52 UR - https://doi.org/10.1002/art.21137 DO - 10.1002/art.21137 ID - Askling2005 ER - TY - JOUR AU - Carmona, L. AU - Gomez-Reino, J. J. AU - Rodriguez-Valverde, V. PY - 2005 DA - 2005// TI - Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists JO - Arthritis Rheum VL - 52 UR - https://doi.org/10.1002/art.21043 DO - 10.1002/art.21043 ID - Carmona2005 ER - TY - JOUR AU - Tubach, F. AU - Salmon, D. AU - Ravaud, P. PY - 2009 DA - 2009// TI - Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry JO - Arthritis Rheum VL - 60 UR - https://doi.org/10.1002/art.24632 DO - 10.1002/art.24632 ID - Tubach2009 ER - TY - JOUR AU - Wolfe, F. AU - Michaud, K. AU - Anderson, J. PY - 2004 DA - 2004// TI - Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy JO - Arthritis Rheum VL - 50 UR - https://doi.org/10.1002/art.20009 DO - 10.1002/art.20009 ID - Wolfe2004 ER - TY - JOUR AU - Getahun, H. AU - Gunneberg, C. AU - Granich, R. PY - 2010 DA - 2010// TI - HIV infection-associated tuberculosis: the epidemiology and the response JO - Clin Infect Dis VL - 50 UR - https://doi.org/10.1086/651492 DO - 10.1086/651492 ID - Getahun2010 ER - TY - JOUR AU - Min, J. AU - Kwon, S. K. AU - Jeong, H. W. PY - 2018 DA - 2018// TI - End-stage renal disease and risk of active tuberculosis: a Nationwide population-based cohort study JO - J Korean Med Sci VL - 33 UR - https://doi.org/10.3346/jkms.2018.33.e341 DO - 10.3346/jkms.2018.33.e341 ID - Min2018 ER - TY - JOUR AU - Dooley, K. E. AU - Chaisson, R. E. PY - 2009 DA - 2009// TI - Tuberculosis and diabetes mellitus: convergence of two epidemics JO - Lancet Infect Dis VL - 9 UR - https://doi.org/10.1016/S1473-3099(09)70282-8 DO - 10.1016/S1473-3099(09)70282-8 ID - Dooley2009 ER - TY - JOUR AU - Christopoulos, A. AU - Saif, M. W. AU - Sarris, E. G. PY - 2014 DA - 2014// TI - Epidemiology of active tuberculosis in lung cancer patients: a systematic review JO - Clin Respir J VL - 8 UR - https://doi.org/10.1111/crj.12094 DO - 10.1111/crj.12094 ID - Christopoulos2014 ER - TY - JOUR AU - Wherry, E. J. PY - 2011 DA - 2011// TI - T cell exhaustion JO - Nat Immunol VL - 12 UR - https://doi.org/10.1038/ni.2035 DO - 10.1038/ni.2035 ID - Wherry2011 ER - TY - JOUR AU - Lazar-Molnar, E. AU - Chen, B. AU - Sweeney, K. A. PY - 2010 DA - 2010// TI - Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis JO - Proc Natl Acad Sci U S A VL - 107 UR - https://doi.org/10.1073/pnas.1007394107 DO - 10.1073/pnas.1007394107 ID - Lazar-Molnar2010 ER - TY - JOUR AU - Barber, D. L. AU - Mayer-Barber, K. D. AU - Feng, C. G. PY - 2011 DA - 2011// TI - CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition JO - J Immunol VL - 186 UR - https://doi.org/10.4049/jimmunol.1003304 DO - 10.4049/jimmunol.1003304 ID - Barber2011 ER - TY - JOUR AU - Tousif, S. AU - Singh, Y. AU - Prasad, D. V. PY - 2011 DA - 2011// TI - T cells from programmed Death-1 deficient mice respond poorly to Mycobacterium tuberculosis infection JO - PLoS One VL - 6 UR - https://doi.org/10.1371/journal.pone.0019864 DO - 10.1371/journal.pone.0019864 ID - Tousif2011 ER - TY - JOUR AU - Sakai, S. AU - Kauffman, K. D. AU - Sallin, M. A. PY - 2016 DA - 2016// TI - CD4 T cell-derived IFN-gamma plays a minimal role in control of pulmonary Mycobacterium tuberculosis infection and must be actively repressed by PD-1 to prevent lethal disease JO - PLoS Pathog VL - 12 UR - https://doi.org/10.1371/journal.ppat.1005667 DO - 10.1371/journal.ppat.1005667 ID - Sakai2016 ER - TY - JOUR AU - Trinath, J. AU - Maddur, M. S. AU - Kaveri, S. V. PY - 2012 DA - 2012// TI - Mycobacterium tuberculosis promotes regulatory T-cell expansion via induction of programmed death-1 ligand 1 (PD-L1, CD274) on dendritic cells JO - J Infect Dis VL - 205 UR - https://doi.org/10.1093/infdis/jir820 DO - 10.1093/infdis/jir820 ID - Trinath2012 ER - TY - JOUR AU - Versteven, M. AU - Bergh, J. M. J. AU - Marcq, E. PY - 2018 DA - 2018// TI - Dendritic cells and programmed Death-1 blockade: a joint venture to combat Cancer JO - Front Immunol VL - 9 UR - https://doi.org/10.3389/fimmu.2018.00394 DO - 10.3389/fimmu.2018.00394 ID - Versteven2018 ER - TY - JOUR AU - Benson, D. M. AU - Bakan, C. E. AU - Mishra, A. PY - 2010 DA - 2010// TI - The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody JO - Blood. VL - 116 UR - https://doi.org/10.1182/blood-2010-02-271874 DO - 10.1182/blood-2010-02-271874 ID - Benson2010 ER - TY - JOUR AU - Alvarez, I. B. AU - Pasquinelli, V. AU - Jurado, J. O. PY - 2010 DA - 2010// TI - Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis JO - J Infect Dis VL - 202 UR - https://doi.org/10.1086/654932 DO - 10.1086/654932 ID - Alvarez2010 ER - TY - JOUR AU - Norris, S. AU - Coleman, A. AU - Kuri-Cervantes, L. PY - 2012 DA - 2012// TI - PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection JO - Viral Immunol VL - 25 UR - https://doi.org/10.1089/vim.2011.0096 DO - 10.1089/vim.2011.0096 ID - Norris2012 ER - TY - JOUR AU - Cao, S. AU - Li, J. AU - Lu, J. PY - 2019 DA - 2019// TI - Mycobacterium tuberculosis antigens repress Th1 immune response suppression and promotes lung cancer metastasis through PD-1/PDl-1 signaling pathway JO - Cell Death Dis VL - 10 UR - https://doi.org/10.1038/s41419-018-1237-y DO - 10.1038/s41419-018-1237-y ID - Cao2019 ER - TY - JOUR AU - Shen, L. AU - Gao, Y. AU - Liu, Y. PY - 2016 DA - 2016// TI - PD-1/PD-L pathway inhibits M.tb-specific CD4(+) T-cell functions and phagocytosis of macrophages in active tuberculosis JO - Sci Rep VL - 6 UR - https://doi.org/10.1038/srep38362 DO - 10.1038/srep38362 ID - Shen2016 ER - TY - JOUR AU - Shen, L. AU - Shi, H. AU - Gao, Y. PY - 2016 DA - 2016// TI - The characteristic profiles of PD-1 and PD-L1 expressions and dynamic changes during treatment in active tuberculosis JO - Tuberculosis (Edinb) VL - 101 UR - https://doi.org/10.1016/j.tube.2016.10.001 DO - 10.1016/j.tube.2016.10.001 ID - Shen2016 ER - TY - STD TI - Barber DL, Sakai S, Kudchadkar RR, et al. Tuberculosis following PD-1 blockade for cancer immunotherapy. Sci Transl Med. 2019;11. https://doi.org/10.1126/scitranslmed.aat2702. ID - ref37 ER - TY - JOUR AU - Meintjes, G. AU - Stek, C. AU - Blumenthal, L. PY - 2018 DA - 2018// TI - Prednisone for the prevention of paradoxical tuberculosis-associated IRIS JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1800762 DO - 10.1056/NEJMoa1800762 ID - Meintjes2018 ER - TY - JOUR AU - Rao, M. a. r. t. i. n. AU - Ligeiro, D. a. r. i. o. AU - Maeurer, M. a. r. k. u. s. PY - 2019 DA - 2019// TI - Precision medicine in the clinical management of respiratory tract infections including multidrug-resistant tuberculosis JO - Current Opinion in Pulmonary Medicine VL - 25 UR - https://doi.org/10.1097/MCP.0000000000000575 DO - 10.1097/MCP.0000000000000575 ID - Rao2019 ER - TY - JOUR AU - Rao, M. AU - Ippolito, G. AU - Mfinanga, S. PY - 2019 DA - 2019// TI - Improving treatment outcomes for MDR-TB - novel host-directed therapies and personalised medicine of the future JO - Int J Infect Dis VL - 80S UR - https://doi.org/10.1016/j.ijid.2019.01.039 DO - 10.1016/j.ijid.2019.01.039 ID - Rao2019 ER - TY - JOUR AU - Lee, J. J. AU - Chan, A. AU - Tang, T. PY - 2016 DA - 2016// TI - Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma JO - Acta Oncol VL - 55 UR - https://doi.org/10.3109/0284186X.2015.1125017 DO - 10.3109/0284186X.2015.1125017 ID - Lee2016 ER - TY - JOUR AU - Fujita, K. AU - Terashima, T. AU - Mio, T. PY - 2016 DA - 2016// TI - Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis JO - J Thorac Oncol VL - 11 UR - https://doi.org/10.1016/j.jtho.2016.07.006 DO - 10.1016/j.jtho.2016.07.006 ID - Fujita2016 ER - TY - JOUR AU - Chu, Y. C. AU - Fang, K. C. AU - Chen, H. C. PY - 2017 DA - 2017// TI - Pericardial tamponade caused by a hypersensitivity response to tuberculosis reactivation after anti-PD-1 treatment in a patient with advanced pulmonary adenocarcinoma JO - J Thorac Oncol VL - 12 UR - https://doi.org/10.1016/j.jtho.2017.03.012 DO - 10.1016/j.jtho.2017.03.012 ID - Chu2017 ER - TY - JOUR AU - He, W. AU - Zhang, X. AU - Li, W. PY - 2018 DA - 2018// TI - Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report JO - Onco Targets Ther VL - 11 UR - https://doi.org/10.2147/OTT.S178246 DO - 10.2147/OTT.S178246 ID - He2018 ER - TY - JOUR AU - Jensen, K. H. AU - Persson, G. AU - Bondgaard, A. L. PY - 2018 DA - 2018// TI - Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer JO - Acta Oncol VL - 57 UR - https://doi.org/10.1080/0284186X.2018.1433877 DO - 10.1080/0284186X.2018.1433877 ID - Jensen2018 ER - TY - JOUR AU - Picchi, H. AU - Mateus, C. AU - Chouaid, C. PY - 2018 DA - 2018// TI - Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment JO - Clin Microbiol Infect VL - 24 UR - https://doi.org/10.1016/j.cmi.2017.12.003 DO - 10.1016/j.cmi.2017.12.003 ID - Picchi2018 ER - TY - JOUR AU - Elkington, P. T. AU - Bateman, A. C. AU - Thomas, G. J. PY - 2018 DA - 2018// TI - Implications of tuberculosis reactivation after immune checkpoint inhibition JO - Am J Respir Crit Care Med VL - 198 UR - https://doi.org/10.1164/rccm.201807-1250LE DO - 10.1164/rccm.201807-1250LE ID - Elkington2018 ER - TY - JOUR AU - Tsai, C. C. AU - Chen, J. H. AU - Wang, Y. C. PY - 2019 DA - 2019// TI - Re-activation of pulmonary tuberculosis during anti-programmed death-1 (PD-1) treatment JO - QJM. VL - 112 UR - https://doi.org/10.1093/qjmed/hcy243 DO - 10.1093/qjmed/hcy243 ID - Tsai2019 ER - TY - JOUR AU - Takata, S. AU - Koh, G. AU - Han, Y. PY - 2019 DA - 2019// TI - Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents JO - J Infect Chemother VL - 25 UR - https://doi.org/10.1016/j.jiac.2018.06.016 DO - 10.1016/j.jiac.2018.06.016 ID - Takata2019 ER - TY - STD TI - Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization 2018. ID - ref50 ER - TY - JOUR AU - Force, U. S. P. S. T. AU - Bibbins-Domingo, K. AU - Grossman, D. C. PY - 2016 DA - 2016// TI - Screening for latent tuberculosis infection in adults: US preventive services task Force recommendation statement JO - JAMA. VL - 316 UR - https://doi.org/10.1001/jama.2016.11046 DO - 10.1001/jama.2016.11046 ID - Force2016 ER - TY - STD TI - Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med. 2000;161:S221–47. ID - ref52 ER - TY - JOUR AU - Morrison, V. A. PY - 2014 DA - 2014// TI - Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies JO - Clin Infect Dis VL - 59 UR - https://doi.org/10.1093/cid/ciu592 DO - 10.1093/cid/ciu592 ID - Morrison2014 ER - TY - JOUR AU - Cognetti, D. M. AU - Weber, R. S. AU - Lai, S. Y. PY - 2008 DA - 2008// TI - Head and neck cancer: an evolving treatment paradigm JO - Cancer. VL - 113 UR - https://doi.org/10.1002/cncr.23654 DO - 10.1002/cncr.23654 ID - Cognetti2008 ER - TY - STD TI - National Institute for Health and Care Excellence (2016) Tuberculosis (NICE Guideline 33). Available at: https://www.nice.org.uk/guidance/ng33/resources/tuberculosis-1837390683589. Accessed 22 Apr 2019 UR - https://www.nice.org.uk/guidance/ng33/resources/tuberculosis-1837390683589 ID - ref55 ER - TY - JOUR AU - Simonsen, D. F. AU - Farkas, D. K. AU - Horsburgh, C. R. PY - 2017 DA - 2017// TI - Increased risk of active tuberculosis after cancer diagnosis JO - J Inf Secur VL - 74 ID - Simonsen2017 ER - TY - JOUR AU - Soh, A. Z. AU - Chee, C. B. E. AU - Wang, Y. T. PY - 2017 DA - 2017// TI - Alcohol drinking and cigarette smoking in relation to risk of active tuberculosis: prospective cohort study JO - BMJ Open Respir Res VL - 4 UR - https://doi.org/10.1136/bmjresp-2017-000247 DO - 10.1136/bmjresp-2017-000247 ID - Soh2017 ER - TY - JOUR AU - Scholmerich, J. PY - 2004 DA - 2004// TI - Postgastrectomy syndromes--diagnosis and treatment JO - Best Pract Res Clin Gastroenterol VL - 18 UR - https://doi.org/10.1016/j.bpg.2004.08.003 DO - 10.1016/j.bpg.2004.08.003 ID - Scholmerich2004 ER - TY - JOUR AU - Dai, G. AU - Phalen, S. AU - McMurray, D. N. PY - 1998 DA - 1998// TI - Nutritional modulation of host responses to mycobacteria JO - Front Biosci VL - 3 UR - https://doi.org/10.2741/A371 DO - 10.2741/A371 ID - Dai1998 ER - TY - JOUR AU - Getahun, H. AU - Matteelli, A. AU - Abubakar, I. PY - 2015 DA - 2015// TI - Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries JO - Eur Respir J VL - 46 UR - https://doi.org/10.1183/13993003.01245-2015 DO - 10.1183/13993003.01245-2015 ID - Getahun2015 ER - TY - JOUR AU - Collins, L. F. AU - Geadas, C. AU - Ellner, J. J. PY - 2016 DA - 2016// TI - Diagnosis of latent tuberculosis infection: too soon to pull the plug on the tuberculin skin test JO - Ann Intern Med VL - 164 UR - https://doi.org/10.7326/M15-1522 DO - 10.7326/M15-1522 ID - Collins2016 ER - TY - JOUR AU - Lewinsohn, D. M. AU - Leonard, M. K. AU - LoBue, P. A. PY - 2017 DA - 2017// TI - Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children JO - Clin Infect Dis VL - 64 UR - https://doi.org/10.1093/cid/ciw778 DO - 10.1093/cid/ciw778 ID - Lewinsohn2017 ER - TY - JOUR AU - Ruan, Q. AU - Zhang, S. AU - Ai, J. PY - 2016 DA - 2016// TI - Screening of latent tuberculosis infection by interferon-gamma release assays in rheumatic patients: a systemic review and meta-analysis JO - Clin Rheumatol VL - 35 UR - https://doi.org/10.1007/s10067-014-2817-6 DO - 10.1007/s10067-014-2817-6 ID - Ruan2016 ER - TY - JOUR AU - Kaplan, M. H. AU - Armstrong, D. AU - Rosen, P. PY - 1974 DA - 1974// TI - Tuberculosis complicating neoplastic disease. A review of 201 cases JO - Cancer. VL - 33 UR - https://doi.org/3.0.CO;2-H DO - 3.0.CO;2-H ID - Kaplan1974 ER - TY - JOUR AU - Libshitz, H. I. AU - Pannu, H. K. AU - Elting, L. S. PY - 1997 DA - 1997// TI - Tuberculosis in cancer patients: an update JO - J Thorac Imaging VL - 12 UR - https://doi.org/10.1097/00005382-199701000-00006 DO - 10.1097/00005382-199701000-00006 ID - Libshitz1997 ER - TY - JOUR AU - Seo, G. H. AU - Kim, M. J. AU - Seo, S. PY - 2016 DA - 2016// TI - Cancer-specific incidence rates of tuberculosis: A 5-year nationwide population-based study in a country with an intermediate tuberculosis burden JO - Medicine (Baltimore) VL - 95 UR - https://doi.org/10.1097/MD.0000000000004919 DO - 10.1097/MD.0000000000004919 ID - Seo2016 ER - TY - JOUR AU - Kamboj, M. AU - Sepkowitz, K. A. PY - 2006 DA - 2006// TI - The risk of tuberculosis in patients with cancer JO - Clin Infect Dis VL - 42 UR - https://doi.org/10.1086/503917 DO - 10.1086/503917 ID - Kamboj2006 ER - TY - JOUR AU - Tasillo, A. AU - Salomon, J. A. AU - Trikalinos, T. A. PY - 2017 DA - 2017// TI - Cost-effectiveness of testing and treatment for latent tuberculosis infection in residents born outside the United States with and without medical comorbidities in a simulation model JO - JAMA Intern Med VL - 177 UR - https://doi.org/10.1001/jamainternmed.2017.3941 DO - 10.1001/jamainternmed.2017.3941 ID - Tasillo2017 ER - TY - JOUR AU - Baddley, J. W. AU - Cantini, F. AU - Goletti, D. PY - 2018 DA - 2018// TI - ESCMID study Group for Infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [I]: anti-tumor necrosis factor-alpha agents) JO - Clin Microbiol Infect VL - 24 UR - https://doi.org/10.1016/j.cmi.2017.12.025 DO - 10.1016/j.cmi.2017.12.025 ID - Baddley2018 ER - TY - JOUR AU - Menzies, D. AU - Adjobimey, M. AU - Ruslami, R. PY - 2018 DA - 2018// TI - Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1714283 DO - 10.1056/NEJMoa1714283 ID - Menzies2018 ER - TY - JOUR AU - Winthrop, K. L. AU - Siegel, J. N. AU - Jereb, J. PY - 2005 DA - 2005// TI - Tuberculosis associated with therapy against tumor necrosis factor alpha JO - Arthritis Rheum VL - 52 UR - https://doi.org/10.1002/art.21382 DO - 10.1002/art.21382 ID - Winthrop2005 ER - TY - JOUR AU - Hsia, E. C. AU - Schluger, N. AU - Cush, J. J. PY - 2012 DA - 2012// TI - Interferon-gamma release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis JO - Arthritis Rheum VL - 64 UR - https://doi.org/10.1002/art.34382 DO - 10.1002/art.34382 ID - Hsia2012 ER - TY - JOUR AU - Dyck, L. AU - Mills, K. H. G. PY - 2017 DA - 2017// TI - Immune checkpoints and their inhibition in cancer and infectious diseases JO - Eur J Immunol VL - 47 UR - https://doi.org/10.1002/eji.201646875 DO - 10.1002/eji.201646875 ID - Dyck2017 ER - TY - JOUR AU - Jurado, J. O. AU - Alvarez, I. B. AU - Pasquinelli, V. PY - 2008 DA - 2008// TI - Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis JO - J Immunol VL - 181 UR - https://doi.org/10.4049/jimmunol.181.1.116 DO - 10.4049/jimmunol.181.1.116 ID - Jurado2008 ER -